Drug Trial Radar · NCT04501874
A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Jul 29, 2020
Primary completion
Jul 27, 2022
Study completion Oct 15, 2022
Sponsor
- Lead sponsor
- Embera NeuroTherapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- Aug 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This is a Phase 2 study in approximately 80 adult subjects with moderate-to-severe Cocaine Use Disorder (CUD).
Conditions
- Cocaine Use Disorder
Interventions
EMB-001Drug
720 mg metyrapone/24 mg oxazepam mg BID
EMB-001 PlaceboDrug
Inactive comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Continuous Abstinence From Cocaine UseTime frame: Week 11 to Week 13
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Pacific Treatment and Research Center, Department of Psychiatry, University of California, San Diego, School of Medicine
San Diego, California
Segal Trials
Miami, Florida
U PENN- Perelman School of Medicine
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.